Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices

Next Previous
Trial Profile

Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REVEAL
  • Sponsors Incyte Corporation

Most Recent Events

  • 03 Jun 2025 According to an Incyte corporation media release, data from the study will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 -15, 2025, in Milan.
  • 15 Jun 2023 Results (n=1053) of a longitudinal analysis in patients (greater or equal to 18 years) with PV who received HU more than or equal to 3 mo prior to study enrollment and did not switch to alternative tx during the observation period or who switched to RUX after previous HU presented at the 28th Congress of the European Haematology Association
  • 01 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top